	4							- C 7	חו	EXCHA		°OMM	ICCI					
FORM 4 UNIT					5 5			ngton, D					1551			ОМВ	APPRO	/AL
Section 16. Form 4 or Form 5 obligations may continue. See													KSHIF			OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* <u>LEONARD JOHN M</u>					2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]								neck al	II applica	able)	g Pers	on(s) to Issi 10% Ow	
(Last)(First)(Middle)C/O INTELLIA THERAPEUTICS, INC.40 ERIE STREET; SUITE 130					3. Date of Earliest Transaction (Month/Day/Year) 08/19/2021								X Officer (give title Other (spec below) below) President and CEO					pecify
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				- 4. I	 If Amendment, Date of Original Filed (Month/Da 								e) X	Form fil	ed by One	d by One Reporting Person		
(St																		
1. Title of Security (Instr. 3)				ction	n 2A. Deemed Execution Date,		3. Transaction Code (Instr.			s Acquired	(A) or	5. Amount of Securities Beneficially Owned Followi		s Illy ollowing	Form: Direct (D) or Indirec		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	<u> </u> т	ransacti	on(s)		ľ	(iiisti. 4)
Common Stock				08/19/2021				М		22,682	Α	\$13. 4	-	741,987			D	
Common Stock				08/19/2021		1		S ⁽¹⁾		9,726	D	\$150.46	⁽²⁾ 732,261		,261	D		
Common Stock				2021	1		S ⁽¹⁾		6,993	D	\$151.50	5 ⁽³⁾	725,268			D		
Common Stock			08/19/2021				S ⁽¹⁾		5,963	D	\$152.3	.3 ⁽⁴⁾ 71),305		D		
Common Stock													58		,415			By Trust ⁽⁵⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)				nstr. Derivative Securities Acquired (A) or Disposed		Expirat	ion Da	ate	of Securi Underlyir Derivativ	ties 1g e Security	Deriv Secu	erivative ecurity 1str. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s)	s Ily	Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
\$13.4	08/19/2021	4		М			22,682	(6)		03/01/2030	Common Stock 22,68		\$0	\$ 0.00 251		7	D	
	6. Form 4 or s may contin n 1(b). Address of RD JOH (Fin LLIA THI TREET; S DGE M. (St Curity (Instr tock tock tock tock tock tock tock tock tock tock tock tock tock tock	6. Form 4 or Form 5 Is may continue. See n 1(b). Address of Reporting Person [*] RD JOHN M (First) LLIA THERAPEUTICS, TREET; SUITE 130 DGE MA (State) Tak curity (Instr. 3) tock tock tock tock tock tock tock tock tock tock tock	6. Form 4 or Form 5 is may continue. See n 1(b). Address of Reporting Person* RD JOHN M (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 DGE MA 02139 (State) (Zip) Table I - N curity (Instr. 3) tock	6. Form 4 or Form 5 's may continue. See n 1(b). Fi Address of Reporting Person* RD JOHN M (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 DGE MA 02139 (State) (Zip) Code took 08/19/ t	6. Form 4 or Form 5 is may continue. See n 1(b). Filed pur Address of Reporting Person* <u>RD JOHN M</u> (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 0GE MA 02139 (State) (Zip) <u>Table I - Non-Derivative</u> (State) (Zip) <u>Curity (Instr. 3)</u> <u>1</u> 2. Transaction Date (Month/Day/Year) tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock <u>08/19/2021</u> tock <u>08/19/2021</u> <u>1</u> A. <u>1</u>	6. Form 4 or Form 5 ' is may continue. See ' in 1(b). Filed pursuant t or Section Address of Reporting Person' RD JOHN M (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 (State) (Zip) Code MA 02139 (State) (Zip) Curity (Instr. 3) Summary (Instr. 3) Curity (Instr. 3) Summary (Instr. 3) Curity (Instr. 3) Summary (Instr. 3) Curity (Instr. 3) Curity (Instr. 3) Curity (Instr. 3) Curity (Instr. 3) Summary (Instr. 3) Curity (Instr. 3) Curity (Instr. 3) Curity (Instr. 3) Summary (Instr. 3) Curity (Instr. 3) Summary (Instr.	6. Form 4 or Form 5 ⁻ in t(b). Filed pursuant to Sec or Section 30 Address of Reporting Person* <u>RD JOHN M</u> (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 OGE MA 02139 (State) (Zip) Table I - Non-Derivative Securit curity (Instr. 3) Cate (State) (Zip) <u>Cate (State) (Zip)</u> <u>Cate (Month/Day/Year)</u> <u>Cate (State) (Zip)</u> <u>Cate (State) (Zip)</u> <u>Cate</u>	6. Form 4 or Form 5 ' is may continue. See ' n 1(b). Filed pursuant to Section 16(c or Section 30(h) of the Address of Reporting Person* RD JOHN M (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 DGE MA 02139 (State) (Zip) Table 1 - Non-Derivative Securities Acc curity (Instr. 3) Cock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 Table I - Derivative Securities Acc (Month/Day/Year) Address of Reporting Person* (Month/Day/Year) A first security (Instr. 3) S. Transaction Date (Reporting Person* Table I - Non-Derivative Securities Acc (Month/Day/Year) tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 tock 08/19/2021 5. Number (Month/Day/Year) A first security (Instr. 3) A Deemed Execution Date, first of the first securities Acc (e.g., puts, calls, varrants Conversion 7. Transaction Date (Month/Day/Year) A first security (Instr. 3) A Deemed First of the first securities Acc (e.g., puts, calls, varrants A first of the first securities Acc (horth/Day/Year) A first security (Instr. 3) A Deemed First of the first securities Acc (e.g., puts, calls, varrants A first of the first securities Acc (horth/Day/Year) A first security (Instr. 3) A data 5 A data 5	6. Form 4 or Form 5 ' s may continue. See n 1(0). Filed pursuant to Section 16(a) of the investme Address of Reporting Person* <u>RD JOHN M</u> (First) (Middle) LLIA THERAPEUTICS, INC. TREET; SUITE 130 <u>OGE MA 02139</u> (State) (Zip) Table I - Non-Derivative Securities Acquired (state) (Zip) Table I - Non-Derivative Securities Acquired (month/Day/Year) <u>Code</u> tock 08/19/2021 Table II - Derivative Securities Acquired (in the first) (Month/Day/Year) Solution Table II - Derivative Securities Acquired (in the first) (Month/Day/Year) Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution Solution 	6. Form 5 is may continue. See n1(0). Filed pursuant to Section 16(a) of the Secur or Section 30(i) of the Investment C Address of Reporting Person* 2. Issuer Name and Ticker or Trading Intellia Therapeutics, Inc. (First) (Middle) LLIA THERAPEUTICS, INC. 3. Date of Earliest Transaction (Month 08/19/2021) OGE MA 02139 (State) (Zip) Table I - Non-Derivative Securities Acquired, Di Code (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. A Deemed Execution Date, (If any (Month/Day/Year)) 3. Transaction Code (Instr. 3) tock 08/19/2021 ✓ M 1 tock 08/19/2021 ≤1 5(1) 1 tock 08/19/2021 5(1) 5 1 tock 08/19/2021 5(1) 5 5 tock 08/19/2021 5 5 5 tock 08/19/2021 5 5	6. Form 40 FÖrm 5 's may continue. See 'n 1(b). Filed pursuant to Section 16(a) of the Securities Exchan or Section 30(h) of the Investment Company Act or Sectin 30(h) of the Investment Company Act or Section 30(h	6. Form 40 rGm 5 is may continue. See in all 0: Filed pursuant to Section 16(a) of the Securities Exchange Act of 120 or Section 30(f) of the Investment Company Act of 1240 or Section 30(f) of Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA] Intellia Therapeutics, Inc. [NTLA	6. Form 40 rGm 5 's may continue. See in 10:) Filed pursuant to Section 18(a) of the Investment Company Act of 1940 or Section 30(h) of Intervestment Company Act of 1940 or Section 30(h) of Intervestment Company Act of 1940 or Section 30(h) of Intervestervestment Company Act of 1940 or Section	6. Event or Form 5's may continue. See on 120. Filed pursuant to Section 13(a) of the Securities Exchange Act of 1340 S. Reliation 20(b) of the Investment Company Act of 1340 Address of Reporting Person* Intellia Therapeutics, Inc. [NTLA] S. Reliation 20(b) of the Investment Company Act of 1240 S. Reliation 20(b) of the Investment Company Act of 1240 (First) (Middle) Intellia Therapeutics, Inc. [NTLA] S. Reliation 20(b) of the Investment Company Act of 1240 S. Reliation 20(b) of the Investment Company Act of 1240 (First) (Middle) Intellia Therapeutics, Inc. [NTLA] S. Reliation 20(b) of the Investment Company Act of 1240 S. Reliation 20(b) of the Investment Company Act of 1240 DGE MA 02139 10(b)	6. Emm 4 or Form 5 's may continue. See in support of the securities Exchange Act of 1934 Securities Securities Exchange Act of 1934 Address of Reporting Person (FIRS) (Middle) 2. Issuer Name and Ticker of Trading Symbol S. Relationship of Check all applicits (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or J. Units DGE MA 02139 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or J. Units (State) (ZiP) 2. Transaction (Month/Day/Year) 6. Individual or J. Units DGE MA 02139 2. Transaction (Month/Day/Year) 6. Individual or J. Units (State) (ZiP) 2. Transaction (Month/Day/Year) 6. Individual or J. Units DGE MA 02139 2. Transaction (Month/Day/Year) 8. Transaction (Month/Day/Year) 8. Transaction (Month/Day/Year) (State) (ZiP) 2. Transaction (Month/Day/Year) 8. Transaction (Month/Day/Year) 8. Transaction (Month/Day/Year) 8. State (Month/Day/Year) tock 08/19/2021	State in output with the maximum control of the securities is control of the maximum compary Act of 1934 State infection of the maximum compary Act of 1934 State infection of the maximum compary Act of 1934 Address of Reporting Person [®] RD JOHN M 2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA] 5. Relationship of Reporting Check all applicable). 5. Relationship of Reporting Check all applicable). State of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Check all applicable). State of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Check all applicable). State of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Check all applicable). State of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Check all applicable). State of Compary Act of 1934 OGE MA 02139 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Person 6. Individual or Joint/Group Person OGE MA 02139 Z. Transaction Month/Day/Year) 2. Securities Acquired (A) or Person S. Amount of Securities Acquired (A) or Pers	State in additional control of the securities is becauting by the investment of company Add rules of regional and regional additional additionadditionaddite additional additional additional additional additio	State of part

1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$150.00 to \$150.96, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$151.02 to \$152.015, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$152.055 to \$152.80, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. 5. Shares held by the John M. Leonard 2015 Irrevocable Trust.

6. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 19, 2021. **Remarks:**

> /s/Glenn Goddard Attorney-In-08/20/2021 Fact

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.